LivingGLP1
Basal insulin

NPH insulin

INS_NPH

Agent
NPH insulin
Dosing
titrated to target
Mechanism
Insulin glargine; detemir; degludec; icodec; NPH
Trials
1
Participants in these arms
22

Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.

Related

    Effects across outcomes

    Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
    ConditionOutcomeWindowVersusEffect (95% CrI)SUCRA
    Type 2 diabetes (adults)HbA1c changeweeks 20 to 36 (target week 26)PlaceboMD -1.10 (-2.13 to 0.60)0.46
    Type 2 diabetes (adults)HbA1c changeweeks 20 to 36 (target week 26)PlaceboMD -0.79 (-2.13 to 1.00)0.47

    Trials